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Abstract
Introduction: The management of posttraumatic cerebrospinal fluid (CSF) rhinorrhoea remains a clinical challenge. Cerebrospinal fistula is a dural 
defect responsible for possible CSF leakage into the contiguous air-filled cavities located at the skull base. The risk of central nervous system infecti-
on in these conditions is severe and can be life threatening. Consequently, a specific CSF biomarker might be used in case of difficult diagnosis of CSF 
rhinorrhoea. CSF Tau protein is a neuronal protein, commonly assessed for diagnosis of Alzheimer Disease (AD). The aim of this study was to determi-
ne whether the Tau protein could be a relevant marker of CSF leakage. 
Materials and methods: Tau protein measurement was performed by enzyme-linked immunosorbent assay in 13 patients with CSF leakage (CSF 
rhinorrhoea group), and 8 patients with spontaneous aqueous rhinorrhoea (non-CSF leakage group). The serum concentration of Tau protein was 
measured by ELISA in both CSF rhinorrhoea group and non-CSF leakage group.
Results: In patients with CSF leakage, CSF Tau protein median concentration was 479 ng/L (197 - 2325 ng/L). On the other hand, the Tau protein 
concentration was below the lower limit of quantification (LLoQ) (< 87 ng/L) in non-CSF leakage group. Serum Tau protein concentration by ELISA 
was also below LLoQ (< 87 ng/L) for all subjects. 
Conclusion: ELISA measurement of Tau protein in rhinorrhoea fluid may be a reliable and relevant marker for detecting the presence of CSF in the 
nasal discharge and sign the existence of a CSF leakage. 
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The diagnosis and management of posttraumatic 
cerebrospinal fluid (CSF) rhinorrhoea remain a clin-
ical challenge (1). Cerebrospinal fistulas (CF) leak-
age is an abnormal communication between the 
subarachnoid space and the air-filled cavities of 
the skull base. The majority of CF is traumatic 
(head trauma, surgery). They occur preferentially 
in areas of bone or meningeal weakness (2). How-
ever, CF can be non-traumatic (idiopathic, congen-
ital malformations, inflammatory processes, tu-
mours, conditions that increase the subarachnoid 
pressure, slowly eroding the bones of the skull 
base). The major risk remains central nervous sys-
tem infection (bacterial meningitis or intracranial 
abscess) which is potentially fatal, despite thera-
peutic agents. CF should also be suspected in cas-
es of recurrent infectious complications of central 
nervous system caused by pyogen bacteria (2). 
The cumulative risk of meningitis was evaluated to 
7.4% per week for the first month after injury and 
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exceeds 85% at 10 years follow-up (3). In many cas-
es, CF regresses spontaneously. 
Nonetheless, a reliable early diagnosis and treat-
ment of CSF leakage is important to prevent infec-
tious complications with appropriate surgery. Cur-
rently, there are only few guidelines for the diag-
nosis of CSF leakage (4). The diagnosis is mainly 
based on clinical features of rhinorrhoea, which 
can be clear, positional, unilateral or bilateral, in-
termittent or unnoticed. High resolution comput-
ed tomography, magnetic resonance imaging and 
invasive procedures are necessary in many cases 
(5). Treatment consists of surgical closure of the 
dural defect. Consequently, it is important to de-
velop biological non-invasive, sensitive, specific 
and reliable methods for the positive diagnosis of 
CSF leaks (5). These methods could be of great in-
terest when imaging is not contributory or not 
possible, especially if the patient has contraindica-
tions to magnetic resonance imaging (pacemaker, 
implantable defibrillator, ferromagnetic intraocu-
lar foreign body, claustrophobia).
Tau protein, discovered in 1975, is an intraneuronal 
protein mainly involved in axonal transport and 
stabilization of microtubules (6). It is now well es-
tablished that an increased concentration of Tau 
protein in CSF is an important biomarker of Alzhei-
mer disease (AD) (6). Tau protein could also be 
measured in CSF of healthy people. Its concentra-
tion is much lower in serum than in CSF (ratio CSF/
serum 10:1), so that Tau protein is usually unde-
tectable in other biological fluids with the current-
ly used assay methods (7).
The discovery of new biological markers is a chal-
lenge for diagnosis and management of posttrau-
matic CSF rhinorrhoea in three main situations: (i) 
when additional radiological or interventional ex-
aminations do not provide evidence of diagnosis; 
(ii) when further examination cannot be per-
formed; (iii) in case of discrepancies between clini-
cal features and radiological examinations.
A specific CSF biomarker should be used for diffi-
cult diagnosis of CSF rhinorrhoea. Tau protein is 
commonly assessed in CSF for diagnosis of AD and 
should be used as a possible specific biomarker of 
CSF. The aim of this study was to evaluate the di-
agnostic value of Tau protein as a marker of CF in 
patients with rhinorrhoea. 
Materials and methods
Subjects 
This study was performed on samples collected 
after medical prescription of Tau protein assay in 
the Reims University Hospital (Reims, France). The 
patients were hospitalized in the Otorhinolaryn-
gology or Neurosurgery department. Patients 
were included in this study from October 2011 to 
December 2016. Three groups of patients were as-
sessed. The CSF rhinorrhoea group included 13 
patients with rhinorrhoea due to CF leakage (7 fe-
males and 6 males; median age 59 years (27-79); 8 
post chirurgical CF leakages and 5 posttraumatic 
CF leakages). The diagnosis of CSF rhinorrhoea 
was confirmed after surgery exploration, associat-
ed in some cases with sodium-fluorescein detec-
tion. The non-CSF leakage group included 8 pa-
tients with spontaneous aqueous rhinorrhoea due 
to viral or allergic rhinopathy (5 women and 3 
men; median age 31 years (18-47)). These patients 
never presented any clinical feature of dural de-
fect, head trauma, meningitis, or meningeal weak-
ness. The sera group included the sera of ten pa-
tients from CSF rhinorrhoea group, three patients 
of non-CSF leakage group and three other healthy 
control patients (7 women and 3 men; median age 
49 years (18-79)). It is therefore important to assay 
in parallel Tau protein in the serum and in the rhi-
norrhoea fluid using the same technique. For each 
patient, rhinorrhoea fluid and serum Tau protein 
concentrations must be assessed in the same way 
to avoid any influence of blood contamination of 
rhinorrhoea sample.
Methods 
All nasal discharge (400 μL) were collected, stored 
and processed in 5 mL polypropylene tubes with-
out additive (ref 62.610.201, Sarstedt, Marnay, 
France). These tubes do not adsorb the Tau protein 
and thus do not affect results (8). They were centri-
fuged for 10 minutes at 2000xg at 4 °C and 300 µL 
of the supernatant was collected in another tube 
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for Tau protein assay and immediately stored at - 
80 °C until use. Tau protein concentrations in CSF 
remains stable at least for one year when the sam-
ple is stored at - 80 °C (9).
Concentration of Tau protein was measured in the 
three groups by a sandwich Enzyme Linked Immu-
noSorbent Assay (ELISA) (INNOTEST hTau Ag, Fu-
jirebio Europe, Ghent, Belgium) according to man-
ufacturer’s instructions. This assay was able to 
quantify total Tau protein, including its six isoforms. 
For each kit, we used the lower limit of quantifica-
tion (LLoQ) according to the manufacturer’s in-
struction. LLoQ may vary between 34 to 87 ng/L 
depending on the kit used in the study. In case of 
concentrations higher than the limit of quantifica-
tion (about 1000 ng/L) the samples were diluted. 
According to the manufacturer recommendations, 
the reference values for the Tau protein in the cer-
ebrospinal fluid measured by ELISA are as follows: 
21 to 51 years: 136 ± 89 ng/L, 51 to 70 years: 243 ± 
127 ng/L, > 70 years: 341 ± 171 ng/L.
The analysis was blind to clinical data and per-
formed when required by the clinician. Tau protein 
measurement was assessed after medical prescrip-
tion and performed routinely in our laboratory. 
Our laboratory is involved in external quality con-
trol program from Alzheimer’s association. No ad-
ditional examinations were carried out and there 
were no risk or constraint for the patient. Approba-
tion by an institutional/national ethics committee 
is not necessary in this case.
Statistical analysis 
The results obtained were analysed using StatEL 
software (Ad Science, Paris, France). Comparison 
between groups was done with Mann-Whitney 
nonparametric test and P values less than 0.05 
were considered statistically significant. Cut-off for 
the best sensibility and specificity of the marker 
was determined with a ROC Curve.
Results 
Tau protein concentration was detected in all pa-
tients in CSF rhinorrhoea group. Its mean concen-
tration was 711 ng/L ranging from 197 ng/L to 
2325 ng/L (median concentration 479 ng/L). By 
contrast, Tau protein was below the LLoQ of the 
ELISA assay (< 87 ng/L) in all samples from non-
CSF leakage group. In all cases, the serum concen-
tration of the Tau protein was also below the LLoQ 
(< 87 ng/L). The concentration of Tau protein was 
significantly higher in the CSF rhinorrhoea group 
than in non-CSF leakage group (P < 0.001).
According to these results, a cut-off of 87 ng/L was 
proposed to discriminate the CSF rhinorrhoea 
group and non-CSF leakage group. With this cut-
off, sensitivity (100%) and specificity (100%) of Tau 
protein measurement by ELISA were excellent 
since Tau protein was present at detectable con-
centration in 100% of CSF rhinorrhoea vs 0% in the 
non-CSF leakage group.
Discussion
In this study, we demonstrate that Tau protein 
measurement in the rhinorrhoea fluid may be a rel-
evant new marker for the diagnosis of CSF leakage 
with a good sensitivity (100%) and good specificity 
(100%). Tau protein was higher in the CSF rhinor-
rhoea group compared to non-CSF leakage group. 
Diagnosis of skull base defects, either traumatic or 
not, is sometimes difficult. Laboratory tests are 
then of great interest. Several biological methods 
have been proposed to differentiate CSF rhinor-
rhoea from other spontaneous rhinorrhoea (for in-
stance, linked to respiratory infections, tears or 
blood contamination). 
Biological investigation of a suspected rhinor-
rhoea consisted for a long time in glucose content 
determination, using glucose oxidase strips. This 
screening test has the advantage of being easily 
done in an emergency context and at the bedside. 
It is fast, inexpensive and widely available. Howev-
er, it has a poor sensitivity and specificity with high 
potential of misdiagnosis (2,4). Moreover, contami-
nation by blood, even in small quantities, can lead 
to false positive results or misinterpretation. These 
restrictions make this test very difficult to interpret 
and it should be abandoned in favour of more reli-
able methods. However, an algorithm was pro-
posed to reinstate its use (9). 
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β2-transferrin and β-trace protein (lipocalin-like 
prostaglandin D or L-PGDS) have also been pro-
posed for the diagnosis of CF (10).
β2-transferrin is a desialylated isoform of transfer-
rin, which is absent in nasal, lachrymal and mu-
cous secretions (2). Several detection techniques 
are possible, mainly immunofixation electrophore-
sis (IFE) and isoelectric focusing (11). However, 
these two techniques can be disrupted by the 
presence of blood in the sample. 
β-trace protein (prostaglandin D2 synthase), a 
member of the family of lipocalins, is the second 
most abundant protein in CSF after albumin 
(12,13). β-trace protein is also measurable in 
healthy subject’s rhinorrhoea fluid. It appeared as 
a good, reliable, reproducible biomarker and was 
more sensitive than β2-transferrin for the diagno-
sis of CSF rhinorrhoea (4). However, the main limi-
tation of the use of β-trace protein as biomarker of 
CSF rhinorrhoea is the cut-off value which ranges 
from 0.25 to 6 mg/L according to the literature 
(14). A cut-off of 1.11 mg/L was determined by 
Risch et al., with 100% specificity and 93% sensitiv-
ity (15). 
The technique used in this study does not allow 
the detection of serum or nasal secretion Tau pro-
tein. Consequently, Tau protein was not detected 
in non-CSF leakage group whereas it was detect-
ed in the case of CSF leakage. The reference values 
of Tau protein in CSF were comparable to those 
found in the CSF rhinorrhoea group. Despite the 
small number of samples in each group, sensitivity 
and specificity of Tau protein measurement by ELI-
SA were excellent since Tau protein was present at 
high concentration in 100% of CSF rhinorrhoea vs 
0% in non-CSF leakage group. Tau concentrations 
did not appear to be associated with any of the 
demographic or clinical characteristics of patients 
with CSF rhinorrhoea. Tau protein measurement 
seems more efficient than other biomarkers com-
monly used to diagnose CSF leakage. Contrarily to 
the previous markers, it was not influenced by 
blood contamination. Blood contamination re-
mains the main confusing factor, which could lead 
to misinterpretation of the currently used bio-
markers. In all cases, the serum concentration of 
Tau protein was below the LLoQ of the assay. Our 
results demonstrate that an increased concentra-
tion of Tau protein in rhinorrhoea was only caused 
by CSF leakage. This is a great advantage since 
blood contamination often occurs after head trau-
ma. Surgery, head trauma or meningitis are often 
associated with limited central nervous system cell 
lysis. Tau protein measurement is commonly used 
in CSF as a marker of neuronal lysis, which could 
explain the highest concentrations, measured in 
some rhinorrhoea samples. This higher concentra-
tion of Tau protein in CSF in case of cell lysis may 
contribute to the sensitivity of Tau protein meas-
urement in CSF rhinorrhoea and overcome the 
false negative β2 transferrin detection reported in 
the case of Streptococcus pneumoniae infection as 
well as the decreased β-trace protein concentra-
tion reported in meningitis (4,16).
By contrast, Tau protein is lower in case of normal 
pressure hydrocephalus, which could lead to false 
negative results (17). To avoid the risk of confusing 
results, a blood sample could be assessed in associ-
ation with rhinorrhoea sample. Blood contamina-
tion remains the main confusing factor, which could 
lead to misinterpretation of biological results (i.e. 
false increased concentration of the β trace protein 
in rhinorrhoea). Tau protein must be assessed in 
both serum and rhinorrhoea fluid, using the same 
technique. According to the ELISA assay used in this 
study, the serum concentration of Tau protein was 
below the LLoQ of the assay, which demonstrate 
that blood contamination did not influence the rhi-
norrhoea of Tau protein. ELISA has also the advan-
tage to require a low sample volume (50 μL). This is 
an important point, given the low volumes availa-
ble for these types of samples. The main disadvan-
tages of the ELISA assay is the high number of pa-
tients needed to completely fill the plate (cost of 
the test) and the duration of the assay (first incuba-
tion lasts overnight). Moreover, for each run, dupli-
cate wells for calibrators, controls, and samples are 
needed. Thus, a major limitation of ELISA is the fact 
that it is not suitable as a rapid and emergency as-
say. The development of automated assay could 
overcome this limitation.
In conclusion, determination of Tau protein by ELI-
SA uses well standardized steps or the sample 
handling procedure, which permits to obtain re-
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producible results. It is widely used in the diagno-
sis of AD although internationally recognized ref-
erence material is not yet available. This pilot study 
is encouraging and suggests that, in the future, it 
could be easily performed routinely and allows re-
liable detection of CSF in the case of rhinorrhoea 
related to a CSF fistula. Contamination by blood 
does not confound the results since serum Tau 
protein was below the LLoQ with this method for 
all samples. Our study shows that Tau protein 
measurement in the rhinorrhoea fluid may be a 
relevant new marker for the diagnosis of CSF leak-
age.
Acknowledgments
The authors thank Fujirebio™ for the reagents used 
in this study. The authors thank Mrs S. Gobert for 
kindly reading and improving the English lan-
guage of the manuscript.
Potential conflict of interest
None declared. 
References
1. Bell RB, Dierks EJ, Homer L, Potter BE. Management of ce-
rebrospinal fluid leak associated with craniomaxillofacial 
trauma. J Oral Maxillofac Surg 2004;62:676-84. https://doi.
org/10.1016/j.joms.2003.08.032
2. Domengie F, Cottier JP, Lescanne E, Aesch B, Vinikoff-Sonier 
C, Gallas S, Herbreteau D. Management of cerebrospinal flu-
id fistulae: physiopathology, imaging and treatment. J Ne-
uroradiol 2004;31:47-59. https://doi.org/10.1016/S0150-
9861(04)96878-2
3. Liao KH, Wang JY, Lin HW, Lui TN, Chen KY, Yen DH, Jeng MJJ. 
Risk of death in patients with post-traumatic cerebrospi-
nal fluid leakage--analysis of 1773 cases. J Chin Med Assoc 
2016,79:58-64. https://doi.org/10.1016/j.jcma.2015.10.002
4. Oakley GM, Alt JA,Schlosser RJ, Harvey RJ, Orlandi RR. Di-
agnosis of cerebrospinal fluid rhinorrhea: an evidence-ba-
sed review with recommendations. Int Forum Allergy Rhinol 
2016;6:8-16. https://doi.org/10.1002/alr.21637
5. Reddy M, Baugnon K.Imaging of Cerebrospinal Flu-
id Rhinorrhea and Otorrhea. Radiol Clin North Am 
2017;55:167-187. https://doi.org/10.1016/j.rcl.2016.08.005
6. Zetterberg H. Tau in biofluids - relation to pathology, ima-
ging and clinical features. Neuropathol Appl Neurobiol 
2017;43:194-199. https://doi.org/10.1111/nan.12378
7. Reiber H. Dynamics of brain-derived proteins in cerebros-
pinal fluid. Clin Chim Acta 2001;310:173-86. https://doi.
org/10.1016/S0009-8981(01)00573-3
8. Sjögren M, Vanderstichele H, Ågren H, Zachrisson O, Edsbag-
ge M, Wikkelsø C, et al. Tau and Aβ42 in cerebrospinal fluid 
from healthy adults 21-93 years of age: establishment of re-
ference values. Clin Chem 2001;47:1776-81.
9. Baker EH, Wood DM, Brennan AL, Baines DL, Philips BJ. New 
insights into the glucose oxidase stick test for cerebrospinal 
fluid rhinorrhoea. Emerg Med J 2005;22:556-7. https://doi.
org/10.1136/emj.2004.022111
10. Schnabel C, Di Martino E, Gilsbach JM, Riediger D, Gressner 
AM, Kunz D. Comparaison of β2-transferrin and β-trace pro-
tein for detection of cerebrospinal fluid and nasal and ear 
fluids. Clin Chem 2004;50:661-3. https://doi.org/10.1373/
clinchem.2003.024158
11. Rodriguez-Capote K, Turner J, Macri J. Evaluation of a 
commercially available carbohydrate deficient transferrin 
kit to detect beta-2-transferrin in cerebrospinal fluid using 
capillary electrophoresis. Clin Biochem 2013;46:1770-3. 
https://doi.org/10.1016/j.clinbiochem.2013.07.001
12. Reiber H, Walther K, Althaus H. Beta-trace protein as sensi-
tive marker for CSF rhinorrhea and CSF otorhea. Acta Neu-
rol Scand 2003;108:359-62. https://doi.org/10.1034/j.1600-
0404.2003.00173.x
13. Bernasconi L, Pötzl T, Steuer C, Dellweg A, Metternich F, Hu-
ber AR. Retrospective validation of a β-trace protein inter-
pretation algorithm for the diagnosis of cerebrospinal fluid 
leakage. Clin Chem Lab Med 2017;55:554-560. https://doi.
org/10.1515/cclm-2016-0442
14. Korem M, Ovadia H, Paldor I, Moses AE, Block C, Eliashar R, 
Hirshoren N. False negative β-2 transferrin in the diagnosis 
of cerebrospinal fluid leak in the presence of Streptococcus 
pneumoniae. Laryngoscope 2015;125:556-60. https://doi.
org/10.1002/lary.24940
15. Risch L, Lisec I, Jutzi M, Podvinec M, Landolt H, Huber 
AR. Rapid, accurate and non-invasive detection of ce-
rebrospinal fluid leakage using combined determina-
tion of beta-trace protein in secretion and serum. Clin 
Chim Acta 2005;351:169-76. https://doi.org/10.1016/j.
cccn.2004.09.008
16. Morell-Garcia D, Bauça JM, Sastre MP, Yañez A, Llom-
part I. Sample-dependent diagnostic accuracy of prosta-
glandin D synthase in cerebrospinal fluid leak. Clin Bio-
chem 2017;50:27-31. https://doi.org/10.1016/j.clinbio-
chem.2016.09.006
17. Jeppsson A, Zetterberg H, Blennow K, Wikkelsø C. Idiopat-
hic normal-pressure hydrocephalus: pathophysiology and 
diagnosis by CSF biomarkers. Neurology 2013;80:1385-92. 
https://doi.org/10.1212/WNL.0b013e31828c2fda
